InterVenn Biosciences vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
InterVenn Biosciences pioneered clinical glycoproteomics with AI-powered liquid biopsy diagnostics for cancer; raised $251M total, received AMA PLA code for non-invasive ovarian cancer test in July 2025.
About
InterVenn Biosciences is a clinical-stage diagnostics company that has pioneered the field of glycoproteomics — the study of proteins modified with sugar molecules (glycans) — combined with artificial intelligence to develop next-generation liquid biopsy tests for cancer detection and treatment monitoring. The company's VOCAL test provides a non-invasive diagnostic for ovarian cancer using a blood draw, and its GlycoKnowPR platform delivers glycoproteomic immunotherapy response assays to help oncologists predict how patients will respond to treatment before administering therapy.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
Key Details
Capabilities & Ecosystem
Also Compare
InterVenn Biosciences vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.